Related Experiment Video

Updated: Nov 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Molecularly Targeted Clinical Trials

Matthew A Smith-Cohn1, Orieta Celiku2, Mark R Gilbert3

  • 1Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Building 37, Room 1016, Bethesda, MD 20892, USA; Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Neurosurgery Clinics of North America
|March 30, 2021
PubMed

Insights

Glioblastoma treatment faces challenges due to genetic diversity and the blood-brain barrier. Targeted synthetic lethality offers a promising new therapeutic avenue for glioblastoma patients.

Area of Science:

  • Neuro-oncology
  • Cancer Therapeutics
  • Molecular Biology

Background:

  • Glioblastoma (GBM) remains a highly lethal brain cancer with limited treatment options.
  • Current therapies (surgery, radiation, chemotherapy) have shown minimal impact on overall survival.
  • Intrinsic tumor complexities like genetic heterogeneity and redundant pathways hinder treatment efficacy.

Purpose of the Study:

  • To review the challenges associated with molecularly targeted therapy in adult glioblastoma.
  • To explore the potential of synthetic lethality as a complementary therapeutic strategy.
  • To discuss current clinical trials and future directions for glioblastoma treatment.

Main Methods:

  • Literature review of glioblastoma molecularly targeted therapies.
  • Analysis of challenges including the blood-brain barrier and tumor heterogeneity.
  • Examination of synthetic lethality principles and their application to glioblastoma.

Main Results:

  • Molecularly targeted agents face significant hurdles in glioblastoma treatment.
  • Patient selection is crucial for therapeutic benefit, as indicated by subset responses.
  • Synthetic lethality presents a promising approach to overcome resistance mechanisms.

Conclusions:

  • Novel therapeutic strategies are urgently needed for glioblastoma.
  • Targeted synthetic lethality holds significant promise for improving glioblastoma outcomes.
  • Future research should focus on patient stratification and innovative therapeutic combinations.
Keywords:
Blood-brain barrierGlioblastomaHeterogenicitySynthetic lethalityTargeted therapy

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.8K